

Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1. (Previously Presented) A room-temperature stable injectable solution for veterinary use comprising from 0.25 to 30% (w/v) of Carprofen (6-chloro-x - methyl-carbazole-2-acetic acid) or a physiologically acceptable salt of Carprofen, and from 0.5 to 20% (w/v) of a poloxamer, and water *q.s.* for injection.
2. (Original) An injectable aqueous solution according to claim 1, wherein the Carprofen salt is in the form of an arginine salt.
3. (Original) An injectable aqueous solution according to claim 1, wherein the Carprofen salt is in the form of a lysine salt.
4. (Previously Presented) An injectable aqueous solution according to claim 1, wherein Carprofen is present in an amount of from 2.5 to 7.5% (w/v).
5. (Previously Presented) An injectable aqueous solution according to claim 1, wherein Carprofen is present in an amount of from 2.5 to 5% (w/v).

6. (Previously Presented) An injectable aqueous solution according to claim 1, comprising arginine in an amount of from 1 to 20% (w/v).

7. (Original) An injectable aqueous solution according to claim 1, wherein an organic solvent is present with the poloxamer.

8. (Original) An injectable aqueous solution according to claim 7, wherein the organic solvent is present in the range of 0.5 to 20% (w/v).

9. (Original) An injectable aqueous solution according to claim 1, wherein the poloxamer is $\text{HO}(\text{CH}_2\text{CH}_2\text{O})_x(\text{CCH}_3\text{HCH}_2\text{O})_y(\text{CH}_2\text{CH}_2)_z\text{H}$ wherein x is 75, y is 30 and z is 75.

10-11. (Cancelled)

12. (Currently Amended) A method of producing a room-temperature stable injectable aqueous solution, ~~for veterinary use~~ comprising:

~~dissolving bringing together~~ Carprofen or a physiologically acceptable salt thereof[[.]] and a poloxamer, ~~and adding sufficient in water for injection, to provide obtain~~ [[a]] an injectable solution comprising ~~containing~~ from 0.25 to 30% (w/v) of Carprofen (6-chloro-x-methyl-carbazole-2-acetic acid) or a physiologically acceptable salt of Carprofen, and from 0.5% to 20% (w/v) of poloxamer.

13. (Previously Presented) A method according to claim 12, wherein the poloxamer is $\text{HO}(\text{CH}_2\text{CH}_2\text{O})_x(\text{CCH}_3\text{HCH}_2\text{O})_y(\text{CH}_2\text{CH}_2)_z\text{H}$ wherein x is 75, y is 30 and z is 75.

14. (Previously Presented) A method of producing an injectable aqueous solution according to claim 12, wherein said method further comprises the inclusion of a preservative.

15. (Previously Presented) An injectable aqueous solution for veterinary use comprising Carprofen 5.0% w/v, arginine 3.1% w/v, poloxamer 5.0% w/v, preservative 0.15% w/v and water q.s.

16. (Previously Presented) A method of producing an injectable aqueous solution comprising bringing together Carprofen 5.0% w/v, arginine 3.1% w/v, poloxamer 5.0% w/v, preservative 0.15% w/v and water q.s to form a mixture.

17. (Previously Presented) A method of producing an injectable aqueous solution according to claim 13, wherein said method further comprises the inclusion of a preservative.

18. (Previously Presented) An injectable aqueous solution according to claim 1, comprising from about 0.5 to about 30% (w/v) of Carprofen (6-chloro-x-methyl-carbazole-2-acetic acid) or a physiologically acceptable salt of Carprofen.

19. (Withdrawn) A method of treating inflammation felines comprising administering the injectable aqueous anti-inflammatory solution of claim 1.

20. (New) The injectable aqueous solution according to claim 1, wherein the injectable aqueous solution is free from precipitate.